February 9, 2016
The Chase Group has been retained by Halozyme Therapeutics to partner with Dr. Dimitrios Chondros as he builds his clinical team. Halozyme is a clinical stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment.